Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 418-420-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Skin Sensitisation: Sensitising (Skin Sens. 1B); OECD 406 (GLP); McEwan & Donald (1999)
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 01 September 1998 - 02 March 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted in accordance with OECD Guideline 406 (1992) and in accordance with GLP. No guideline deviations were recorded during the study. Validity criteria were met.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- Study conducted prior to LLNA Guideline adoption & prior to REACH coming into force.
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS- Source: David Hall Limited, Darley Oaks, Newchurch, Burton-on-Trent, Staffordshire- Age at study initiation: < 1 year old- Weight at study initiation: 283-408 g- Housing: Aluminium cages (48 x 61 x 25 cm) with a grid floor, beneath which was an absorbent paper lined tray- Diet (e.g. ad libitum): Guinea Pig Deit FD1, supplied by Special Diets Services Ltd, ad libitum. Organic cabbage also supplied, when available.- Water (e.g. ad libitum): Mains water supplied ad libitum. Water analysed twice annually for dissolved materials, heavy metals, pesticide residues, pH, nitrites and nitrates.- Acclimation period: minimum of 7 daysENVIRONMENTAL CONDITIONS- Temperature (°C): mean min/mean max: 19/20 °C- Humidity (%): 25 - 51- Air changes (per hr): 15- Photoperiod (hrs dark / hrs light): 12:12, light:darkIN-LIFE DATES: From: 03 Novemeber 1998 To: 29 December 1998
- Route:
- intradermal and epicutaneous
- Vehicle:
- maize oil
- Concentration / amount:
- Intradermal Injection (% TBE): 5 (0.1 mL)Topical Application (% TBE): 75 (0.5 mL)
- Day(s)/duration:
- 48h (epicutaneous)
- Adequacy of induction:
- highest concentration used causing mild-to-moderate skin irritation and well-tolerated systemically
- No.:
- #1
- Route:
- epicutaneous, occlusive
- Vehicle:
- maize oil
- Concentration / amount:
- % TBE = 75 (0.5 mL)
- Day(s)/duration:
- 24h
- Adequacy of challenge:
- highest non-irritant concentration
- No. of animals per dose:
- Dose Range Test - Intradermal Injection: 4Dose Range Test - Topical Application: 2Dose Range Test - Challenge: 2MAIN TEST - Control: 5MAIN TEST - Test Group: 10
- Details on study design:
- DOSE LEVELSDose levels for induction were based on the dose ranging results and were such that necrosis or severe reactions are not produced. Dose levels for dose ranging for challenge were selected based on the dose ranging for topical induction results. These were a range of 4 levels and were used to determine the maximum non-irritant concentration for use at challenge. The dose for challenge was selected based on the dose ranging for challenge results and was the highest concetration that did not cause irritation. ROUTE AND MEANS OF ADMINISTRATIONDose ranging for induction was conducted via intradermal injections and topical application of different concentrations of the test material.For intradermal injections, hair was clipped from the scapula region of the animals (ca. 4 x 6 cm patch). The following day each animal was treated with 4 different concentrations of TBE; 2 animals were treated at 0.5, 2, 5 and 10 % TBE and 2 animals were treated with 20, 40, 60 and 75 % TBE.For topical application, hair was clipped from the flansk of the animals (4 x 6 cm patch). The following day each animal was treated with topically applied test item under Webril patches. Two animals were treated at the following concetration; 10, 25, 50 and 75 % TBE. The patches were covered and aluminium foil and wrapped in occlusive tape and a bandage. Patches were removed after 48 h contact. The test sites were wiped with maize oil and delineated.MAIN TESTFifteen animals (10 test and 5 control animals) had their hair clipped across the scapular region (4 x 6 cm patch). The following day each animal was treated with 6 intradermal injections as follows;Test group: 1. 50 % aqueous FCA (upper left), 2. as previous (upper right), 3. 10 % TBE in maize oil (1:1 v/v) (mid left) (concentrartion = 5 % TBE), 4. as previous (mid right), 5. maize oil: 50 % FCA aqueous (1:1 v/v) (lower left), 6. as previous (lower right).Control group: as per test group with the exception that injection 3 and 4 were maize oil only (no TBE).Six days after the intradermal injections, the hair was clipped from the scapular region of each animal (as before). The area was treated with 0.5 mL of 10 % sodium lauryl sulphate (SLS).The following day the test group had 75 % TBE topically applied to each animal. The control group were treated with maize oil. Each application was covered with a Webril patch (2 x 4 cm), aluminium foil, occlusive tape and an elastic bandage. The patches were removed after 48 h contact and wiped with maize oil.Thirteen days after topical application, hair was clipped from the flanks of each animals. The following day, test material and application vehicle were applied topically to each animal control and test group animals (challenge test). Each topical application was covered by a Webril patch, aluminium foil, occlusive tape and an elastic bandage. The patches were removed 24 h after application. The test site was wiped with maize oil, clipped and delineated.Observations in the main test were conducted for animal viability (twice daily), clinical signs and test site skin reactions (24 h and 48 h (challenge only)). Skin reactions were graded as follows;0 - no visible change1 - discrete or patchy erythema2 - moderate and confluent erythema3 - intense erythema and swellingBody weight of the animals used in the main test were measured prior to induction and after the final timepoint of the challenge test. After the final challenge test sampling interval, all animals were sacrificied by exposure to CO2.
- Challenge controls:
- See above
- Positive control substance(s):
- yes
- Remarks:
- MBT (5 % injection and 25 % topical concentrations w/ maize oil) was completed on 13 July 1998 using Dunkin-Hartley guinea pigs.
- Positive control results:
- The ability of the laboratory to identify a mild/ moderate sensitiser was completed a 6 monthly intervals. The latest test was conducted on 13 July 1998 using MBT at a dose level of 25 % w/v in maize oil. 100 % of the test group animals and none of the control group animals reacted positively.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- n/a
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- 0
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: n/a. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: 0.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 75 % TBE
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- 0
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 75 % TBE. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: 0.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- 0
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: 0.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 75 % TBE
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- 0
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 75 % TBE. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: 0.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 0
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- 0
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 0. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: 0.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 75 % TBE
- No. with + reactions:
- 9
- Total no. in group:
- 10
- Clinical observations:
- 0
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 75 % TBE. No with. + reactions: 9.0. Total no. in groups: 10.0. Clinical observations: 0.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 0
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- 0
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 0. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: 0.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 75 % TBE
- No. with + reactions:
- 8
- Total no. in group:
- 10
- Clinical observations:
- 0
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 75 % TBE. No with. + reactions: 8.0. Total no. in groups: 10.0. Clinical observations: 0.
- Interpretation of results:
- Category 1B (indication of skin sensitising potential) based on GHS criteria
- Remarks:
- Migrated information
- Conclusions:
- Under the conditions of the study, TBE is considered to be a sensitiser in guinea pigs.
- Executive summary:
The delayed hypersensitivity of a test material, TBE was investigated by means of a Magnusson-Kilgman Maximisation Test in guinea pigs.
The Magnusson-Kligman Maximisation Test comprised of two procedures; induction and challenge. The induction procedure exposed guinea pigs to the test material via two routes, namely intradermal injection and topical application. The animals were also exposed to a adjuvant material via intradermal injection, followed by the challenge exposure to the test material via topical application.
During the study, the test group (10 animals) were exposed to 5 % TBE via interdermal injection and 75 % TBE via topical application. The control group (5 animals) were exposed to the vehice solution, maize oil, only at this point.
The proceeding challenge test, with 75 % TBE topically applied to all test animals, saw a 90 % positive response in the test group animals and no response in the control animals.
Under the conditions of the test, TBE is considered to be a sensitiser in guinea pigs.
Reference
Table 1 Body Weight Measurements
Group | Cage | Animal | Body Weight (g) | ||
Start of Study | End of Study | Weight Gain | |||
Control | 1 | 1 | 369 | 702 | 333 |
2 | 407 | 728 | 321 | ||
3 | 376 | 736 | 360 | ||
4 | 398 | 603 | 205 | ||
5 | 342 | 629 | 287 | ||
Test | 2 | 1 | 344 | 575 | 231 |
2 | 359 | 630 | 271 | ||
3 | 413 | 816 | 403 | ||
4 | 353 | 576 | 223 | ||
5 | 344 | 575 | 231 | ||
3 | 1 | 334 | 634 | 300 | |
2 | 361 | 617 | 256 | ||
3 | 329 | 514 | 185 | ||
4 | 358 | 576 | 218 | ||
5 | 338 | 514 | 176 |
Table 2 Challenge Reaction Scores
Group | Rep | % TBE/ Time after patch removal (h) | % TBE / Response | % TBE / % Positive | |||||
0 | 75 | ||||||||
24 | 48 | 24 | 48 | 0 | 75 | 0 | 75 | ||
Control | 1 | 0 | 0 | 0 | 0 | - | - | 0 | 0 |
2 | 0 | 0 | 0 | 0 | - | - | |||
3 | 0 | 0 | 0 | 0 | - | - | |||
4 | 0 | 0 | 0 | 0 | - | - | |||
5 | 0 | 0 | 0 | 0 | - | - | |||
Test | 1 | 0 | 0 | 2 | 2 | - | + | 0 | 90 |
2 | 0 | 0 | 0 | 0 | - | - | |||
3 | 0 | 0 | 1 | 1 | - | + | |||
4 | 0 | 0 | 1 | 1 | - | + | |||
5 | 0 | 0 | 3 | 2 | - | + | |||
6 | 0 | 0 | 2 | 2 | - | + | |||
7 | 0 | 0 | 1 | 0 | - | + | |||
8 | 0 | 0 | 2 | 2 | - | + | |||
9 | 0 | 0 | 1 | 0 | - | + | |||
10 | 0 | 0 | 1 | 1 | - | + |
Skin reactions scored as described in methods section
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
According to CLP (1272/2008, as amended) criteria, the substance is classfied as a category 1B sensitiser (Skin Sens. 1B).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.